Day One Biopharmaceuticals, Inc.
DAWN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $40 | $34 | $31 | $29 |
| % Growth | 17.4% | 10.2% | 5.3% | – |
| Cost of Goods Sold | $4 | $4 | $3 | $3 |
| Gross Profit | $35 | $30 | $28 | $26 |
| % Margin | 88.7% | 88.9% | 90.6% | 89.8% |
| R&D Expenses | $31 | $36 | $40 | $62 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $28 | $29 | $29 | $30 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $60 | $65 | $69 | $92 |
| Operating Income | -$24 | -$35 | -$41 | -$65 |
| % Margin | -60.9% | -103.1% | -133.5% | -223.7% |
| Other Income/Exp. Net | $5 | $5 | $5 | $6 |
| Pre-Tax Income | -$20 | -$30 | -$36 | -$59 |
| Tax Expense | $0 | $0 | $0 | $6 |
| Net Income | -$20 | -$30 | -$36 | -$66 |
| % Margin | -49.6% | -89.4% | -117% | -225% |
| EPS | -0.19 | -0.29 | -0.35 | -0.7 |
| % Growth | 34.5% | 17.1% | 50% | – |
| EPS Diluted | -0.19 | -0.29 | -0.35 | -0.7 |
| Weighted Avg Shares Out | 103 | 103 | 103 | 94 |
| Weighted Avg Shares Out Dil | 103 | 103 | 103 | 94 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $5 | $5 | $6 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$19 | -$29 | -$35 | -$58 |
| % Margin | -47.2% | -86.6% | -114.1% | -200.2% |